211 related articles for article (PubMed ID: 9816095)
1. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
2. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.
Salgaller ML; Weber JS; Koenig S; Yannelli JR; Rosenberg SA
Cancer Immunol Immunother; 1994 Aug; 39(2):105-16. PubMed ID: 7519125
[TBL] [Abstract][Full Text] [Related]
3. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
Slingluff CL; Colella TA; Thompson L; Graham DD; Skipper JC; Caldwell J; Brinckerhoff L; Kittlesen DJ; Deacon DH; Oei C; Harthun NL; Huczko EL; Hunt DF; Darrow TL; Engelhard VH
Cancer Immunol Immunother; 2000 Mar; 48(12):661-72. PubMed ID: 10752474
[TBL] [Abstract][Full Text] [Related]
4. Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients.
Yamasaki S; Okino T; Chakraborty NG; Adkisson WO; Sampieri A; Padula SJ; Mauri F; Mukherji B
Cancer Immunol Immunother; 1995 Apr; 40(4):268-71. PubMed ID: 7750125
[TBL] [Abstract][Full Text] [Related]
5. A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes.
Larrieu P; Renaud V; Godet Y; Jotereau F; Fonteneau JF
Cancer Immunol Immunother; 2008 May; 57(5):745-52. PubMed ID: 18097665
[TBL] [Abstract][Full Text] [Related]
6. PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting.
Labarrière N; Gervois N; Bonnin A; Bouquié R; Jotereau F; Lang F
Cancer Immunol Immunother; 2008 Feb; 57(2):185-95. PubMed ID: 17646986
[TBL] [Abstract][Full Text] [Related]
7. T cell recognition of melanoma antigens in association with HLA-A1 on allogeneic melanoma cells.
Chen Q; Smith M; Nguyen T; Maher DW; Hersey P
Cancer Immunol Immunother; 1994 Jun; 38(6):385-93. PubMed ID: 8205560
[TBL] [Abstract][Full Text] [Related]
8. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules.
So T; Hanagiri T; Chapiro J; Colau D; Brasseur F; Yasumoto K; Boon T; Coulie PG
Cancer Immunol Immunother; 2007 Feb; 56(2):259-69. PubMed ID: 16758204
[TBL] [Abstract][Full Text] [Related]
9. CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion.
Dadmarz R; Sgagias MK; Rosenberg SA; Schwartzentruber DJ
Cancer Immunol Immunother; 1995 Jan; 40(1):1-9. PubMed ID: 7828162
[TBL] [Abstract][Full Text] [Related]
10. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
Seiter S; Monsurro V; Nielsen MB; Wang E; Provenzano M; Wunderlich JR; Rosenberg SA; Marincola FM
J Immunother; 2002; 25(3):252-63. PubMed ID: 12000867
[TBL] [Abstract][Full Text] [Related]
11. Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1.
Hanagiri T; van Baren N; Neyns B; Boon T; Coulie PG
Cancer Immunol Immunother; 2006 Feb; 55(2):178-84. PubMed ID: 16187089
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A.
Hayashi Y; Hoon DS; Park MS; Terasaki PI; Morton DL
Cancer Immunol Immunother; 1992; 34(6):419-23. PubMed ID: 1373343
[TBL] [Abstract][Full Text] [Related]
13. Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells.
Jantscheff P; Spagnoli G; Zajac P; Rochlitz CF
Cancer Immunol Immunother; 2002 Sep; 51(7):367-75. PubMed ID: 12192536
[TBL] [Abstract][Full Text] [Related]
14. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
[TBL] [Abstract][Full Text] [Related]
15. A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.
Larrieu P; Ouisse LH; Guilloux Y; Jotereau F; Fonteneau JF
Cancer Immunol Immunother; 2007 Oct; 56(10):1565-75. PubMed ID: 17318652
[TBL] [Abstract][Full Text] [Related]
16. Autologous tumor-specific cytotoxic T lymphocytes in a patient with lung adenocarcinoma: implications of the shared antigens expressed in HLA-A24 lung cancer cells.
Takenoyama M; Yoshino I; Fujie H; Hanagiri T; Yoshimatsu T; Imabayashi S; Eifuku R; Nomoto K; Yasumoto K
Jpn J Cancer Res; 1998 Jan; 89(1):60-6. PubMed ID: 9510477
[TBL] [Abstract][Full Text] [Related]
17. Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck.
Hald J; Rasmussen N; Claesson MH
Cancer Immunol Immunother; 1995 Oct; 41(4):243-50. PubMed ID: 7489567
[TBL] [Abstract][Full Text] [Related]
18. Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion.
Hom SS; Rosenberg SA; Topalian SL
Cancer Immunol Immunother; 1993; 36(1):1-8. PubMed ID: 8422663
[TBL] [Abstract][Full Text] [Related]
19. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope.
Schreurs MW; Kueter EW; Scholten KB; Kramer D; Meijer CJ; Hooijberg E
Cancer Immunol Immunother; 2005 Jul; 54(7):703-12. PubMed ID: 15726360
[TBL] [Abstract][Full Text] [Related]
20. Analysis of T cell receptor alpha beta variability in lymphocytes infiltrating melanoma primary tumours and metastatic lesions.
Schøller J; thor Straten P; Birck A; Siim E; Dahlström K; Drzewiecki KT; Zeuthen J
Cancer Immunol Immunother; 1994 Oct; 39(4):239-48. PubMed ID: 7954526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
